Open/close main nav Menu Menu MYMETRO Collapse + - ER/URGENT CARE
MyMetro
  • Emergency & Urgent Care

    Is this an Emergency?

    In an emergency, seconds count. If you are alarmed by unusually severe symptoms, seek immediate care. Please call 911 if you feel your condition is life threatening. If a poison is involved, please call Grand Rapids Poison Control Center at (800) 222-1222.

    When to go to the Emergency Room When to go to Urgent Care
  • Hospital ER
    NOW OPEN

    Emergency Room Hours:
    24 hours a day, 7 days a week

    • Directions to the ER

      5900 BYRON CENTER AVE SW

      WYOMING, MI

      (616) 252-7200

      map
  • Urgent Care

    Urgent Care Hours:
    Open 9 am - 9 pm, 7 days a week

    • Directions to Urgent Care

      4055 CASCADE RD SE

      GRAND RAPIDS, MI

      (616) 252-4010

      map
  • Clinical Trials

    Current Enrolling Trials

    For more information on any of the studies listed below, please e-mail research@metrogr.org.

    CANCER

    Condition: Breast Cancer
    The purpose of this research is to study is to learn whether alpelisib, when added to a marketed standard drug (fulvestrant), helps to reduce the growth of breast cancer cells in people with hormone receptor-positive, HER2-negative advanced breast cancer.
    Principal Investigator: Michael Zakem, DO
    Find this study on clinicaltrials.gov:  https://clinicaltrials.gov/ct2/show/NCT02437318?term=SOLAR-1&rank=1

    The National Cancer Institute (NCI) has designated the National Cancer Institute Community Oncology Research Program (NCORP) to provide cutting edge clinical cancer trials to our community.
    For more information about CRCWM and the studies offered at Metro Health Cancer Center visit https://www.crcwm.org/protocols

     
    PERIPHERAL ARTERY DISEASE


    LimFlow
    Condition: Critical Limb Ischemia
    The purpose of the research is to study a new device designed to create a connection between an artery and a vein located below the knee. This device is called the LimFlow Stent Graft System.
    Principal Investigator: Jihad Mustapha, MD
    Find this study on clinicaltrials.gov: “https://clinicaltrials.gov/ct2/show/NCT03124875?term=Limflow&rank=1″>


    PROTEON BTK
    Condition: Peripheral Artery Disease (PAD)
    The purpose of the research study is to test the safety of an experimental drug called Vonapanitase in patients with PAD.
    Principal Investigator: Jihad Mustapha, MD
    Find this study on clinicaltrials.gov:  https://clinicaltrials.gov/ct2/show/NCT02956993?term=PROTEON&rank=2

    VOYAGER
    Condition: Peripheral Artery Disease (PAD)
    The purpose of study is to test whether rivaroxaban added to standard of care treatment, when compared to placebo, has the potential to reduce the incidence of the clinical events related to the clots and complications of the heart and brain (CV death, MI, or stroke) or the legs (acute limb ischemia or major amputation) in patients who had undergone recent procedure(s) to improve the blood flow of their legs.
    Principal Investigator: Jihad Mustapha, MD
    Find this study on clinicaltrials.gov:  https://clinicaltrials.gov/ct2/show/NCT02504216?term=VOYAGER&rank=5

    LUTONIX BTK
    Condition: Peripheral Artery Disease (PAD)
    The goal of this research is to learn more about the benefits of using the Lutonix Drug-Coated Balloon catheter (formerly, Moxy Drug-Coated Balloon catheter) and to gather more data to show it’s safe when treating people with narrowed leg blood vessels.
    Principal Investigator: Jihad Mustapha, MD
    Find this study on clinicaltrials.gov: 

    SPA – 2D Perfusion
    Condition: Peripheral Artery Disease (PAD)
    The purpose of this research is to collect information regarding Philips Healthcare (study sponsor) 2D Perfusion software including procedural steps and how it is used by the physician during your procedure.
    Principal Investigator: Larry Diaz, MD
    Find this study on clinicaltrials.gov:  a>

    PRIME Registry
    Condition: Peripheral Artery Disease (PAD)
    The purpose of this research is to evaluate immediate and long-term outcomes of endovascular revascularization in patients with Critical Limb Ischemia (CLI) and advanced PAD.
    Principal Investigator: Jihad Mustapha, MD
    Find this study on clinicaltrials.gov: 
    https://clinicaltrials.gov/ct2/show/NCT02786173?term=PRIME&rank=5

    HEART DISEASE

    Plexa Registry
    Condition: Fast or Irregular Heart Rhythms
    The purpose of this research is to confirm the long-term safety and reliability of the Plexa lead used with a BIOTRONIK ICD or CRT-D.
    Principal Investigator: Dr. Matthew Sevensma
    Find this study on clinicaltrials.gov:https://clinicaltrials.gov/ct2/show/NCT03103503?term=plexa+registry&rank=1

  • joseph.weller@metrogr.org